Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.

  title={Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.},
  author={Andrea Rocca and Alberto Farolfi and Sara Bravaccini and Alessio Schirone and Dino Amadori},
  journal={Expert opinion on pharmacotherapy},
  volume={15 3},
INTRODUCTION The cyclin D-cyclin-dependent kinases 4 and 6 (CDK4/6)-retinoblastoma (Rb) pathway, governing the cell cycle restriction point, is frequently altered in breast cancer and is a potentially relevant target for anticancer therapy. Palbociclib (PD 0332991) , a potent and selective inhibitor of CDK4 and CDK6, inhibits proliferation of several Rb-positive cancer cell lines and xenograft models. AREAS COVERED The basic features and abnormalities of the cell cycle in breast cancer are… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 33 extracted citations

Precision Molecular Pathology of Bladder Cancer

Molecular Pathology Library • 2018
View 2 Excerpts


Publications referenced by this paper.
Showing 1-10 of 86 references

key mechanisms of A

JL Dean, C Thangavel, AK McClendon, cancer et al. Therapeutic CDK46 inhibition in breast
Rocca et al. 418 Expert Opin. Pharmacother. • 2014
View 4 Excerpts
Highly Influenced

Cell cycle, CDKs and cancer: a changing paradigm

Nature Reviews Cancer • 2009
View 14 Excerpts
Highly Influenced

A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer

A DeMichele, AS Clark, D Heitjan
J Clin Oncol • 2013
View 4 Excerpts
Highly Influenced

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…